Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
the stocks that I have not hoped for are the ones I have done really well in because I haven't had to hope for anything...I did my relentless DD on them and I haven't worried about the day to day fluctuations....go with your gut...
Why ChromaDex Has Monster Potential In The Obesity Market....
http://www.trefis.com/stock/cdxc/articles/128382/why-chromadex-has-monster-potential-in-the-obesity-market/2012-06-22
yeah I was thinking that and there must be more to go to make the 1,333,333. still a great commitment to cdxc
INSIDERS BUYS: Honig bought 74,787 shs yesterday also
I think investors are getting in at this level in a hidden gem..I haven't owned it very long and never never buy stocks under 3.00 but in all my DD I couldn't find any reason not to own it..plus I do believe in following the $$$...looks who's in it and buying up shares...just my opinion though
INSIDER BUYS...Brauser bought 83,498 shs yesterday also
no it's great...u had said CEO so I was looking for Frank Jaksch buy
thanks
did u mean Frost then not the CEO Frank Jaksch...Frost bought 600,000 shs
where are you finding that info....it is not showing on nasdaq like frost's buy...thanks
someone on yahoo mb just said Frost bought 600,000 shs last week
@ Burr...
there is a video on youtube with Jaksch talking about split..they voted it in last year so they would be ready to move up to new listing with exchange...no news yet on that
peer-reviews can take 3 months and sometimes revisions to the paper are made...
this was the comment made in pr june 13th...
Data analyses from the trial on the effects of pTeroPure on blood pressure, triglycerides, cholesterol and oxidative stress are currently underway, and results are expected to be made public following acceptance in a peer-reviewed journal. The study was a collaboration between the University of Mississippi and ChromaDex.
data analyses ....are currently underway
once they analyse the data they still have to write the paper for the journal before they can have it peer-reviewed....
that is why I was saying I wish we could see a timeline here
I would love to know if the data analysis is done and if the peer review is underway because that is what will determine the time of human study results
Last Friday, Aspara Biotechnology Research published an article to help its owners profit from a self-disclosed short position in Opko Health ,,,,,http://seekingalpha.com/article/667561-opko-health-shorts-likely-to-get-frostbite?source=email_rt_article_title&ifp=0
I found this very interesting from Monday, October 31, 2005.....
http://catablast.blogspot.com/2005/10/phil-frost-does-it-again-tevaivax.html
It doesn't happen overnight but this is what you are buying into when you buy OPK.....http://www.fundinguniverse.com/company-histories/ivax-corporation-history/
couldn't help myself today..he pi**ed me off with his jaded crap articles..and I know yahoo mb's get out of control but someone has to comment some common sense over there too...I own opk and I own cdxc among a lot of other stocks but I have to say I sticking with both of these...especially cdxc...there is something big here..I just know it
Rebut...Opko Health: Shorting Is The Best Diagnosis [View article]
Gee, that's a pretty long article about what you think about OPKO and all the reasons why you took a short position on OPK.
But I am long OPK, and think that some of those "reasons" that you enumerate, are probably why so many other people also decided to take a short position on OPK and OPK is now one of the largest "Short Traps".
According to the data in Yahoo, as of last month, there are more than 33 millions short shares, which is about 24.10% of the float, and it would take more than 23 trading days, or more than 4 weeks at the current average volume, if all the shorts wanted to cover.
I don't want to make too long a comment, but since your article is long,lets just look at some of your points.
You Said:
"Operationally, the Claros device remains unproven. Numerous questions surround just how profitable the Claros system will turn out to be."
However, Technology Review commented:
"Claros uses microfluidics technology, which allows for the manipulation of fluids on a chip at microscopic scales, to develop inexpensive, easy-to-use diagnostic devices that can be deployed at the point of care, whether in a doctor's office or at a patient's bedside.
Those tests get results quickly without having to be sent out to a lab for analysis and allow physicians to track certain disease-related markers more often and more thoroughly.
The market for point-of-care diagnostics could potentially be huge because of the benefits it offers. Patients benefit from getting results at the time of their visit; doctors and insurers benefit from a less complicated process with less overhead.
Claros's prostate-cancer test has been approved for use in Europe, and the company is currently seeking approval to market it from the U.S. Food and Drug Administration."
And OPKO has said that the more specific PSA test they have developed after the novel biomarkers they licensed from
Arctic Partners could avoid more than 60% of biopsies that are been done on "false postive" results of the current PSA test.
They wil be also expect to market a Vitamin D and Folic Acid test this year. To have a better answer to your question of "how profitable the Claros system will be", better look at the slides of the latest presentation, which are still available at OPKO's web page.
Regarding the Molecular Diagnostics,
You said:
"Simply put, Kodadek's tests did not identify a biomarker, which is the minimum of what Opko would need in order to create a commercially viable diagnostic blood test."
However, James M. Anderson, M.D., Ph.D., director of the National Institutes of Health (NIH) Division of Program Coordination, Planning, and Strategic Initiatives , has a much different opinion, since he said:
"Dr. Kodadek has conceived a new approach for identifying antibody biomarkers of human disease that bypasses the conventional, but difficult, step of identifying the natural antigens or antigen mimics.
The results in the paper suggest great potential for using this approach to rapidly develop diagnostic biomarkers for a variety of significant human diseases.
Such boldness to challenge conventional paradigms to achieve important scientific advances is a hallmark of the NIH Director's Pioneer Award Program, which supported much of this research." http://bit.ly/MAnNwk
Concerning Dr. Phillip Frost,
You said:
"Frost has had some successes, but he has had plenty of spectacular failures."
But apparently wirh only "some successes" and "plenty of spectacular failures" he became a billionaire and those that invested with him became multimillionaires.
You also said:
"In my opinion. Frost's historical track record is very patchy.", and that you plan to write a future article that will elaborate on why you believe it's a mistake to invest in OPK because Frost is purchasing the stock.
But before you write that future article, it seems you probably should read a little about Dr. Frost, so that your future article won't have as many inaccuracies as the present one.
This article on Wikipedia could be one for you to start reading:
Phillip Frost MD Biography at Wikipedia:
http://bit.ly/KrgwVr
On this other article at Bloomberg-BusinessWeek, on OPKO.where there is also a list of Dr.Frost's "Board Memberships and "Other Affiliations", that may be of help to you:
http://bit.ly/MAnNwn
And we better not make any comments on many other OPKO's assets, since you didn't mention any of those on your long tirade and diatribe of OPKO
For example, FineTech, which through its FDA registered facility in Nesher, Israel, manufactures commercial APIs for sale or license to pharmaceutical companies in the United Sates, Canada, Europe and Israel.
Or CURNA, which is engaged in the discovery of new drugs for the treatment of a variety of illnesses, including cancer, heart disease, metabolic disorders and a range of genetic anomalies.
another comment to his SA
Gee, apparently you din't read my previous note.
I told you to at least read the article of Wikipedia before going into your new long,inaccurate tirade and diatribe on Dr.P.Frost.
Yes, Dr. Frost was one of the first and largest investors in Protalix BioTherapeutics, investing $24 million in the company that would later go on to develop an FDA-approved treatment for Gaucher disease.
And $24 million is not much, compared to his $33 million gift to the School of Music at the University of Miami, or the $35 millions towards the construction of the Miami Science Museum, or his donations to the Art Museum at FIU, or the millions he has donated to Scripps Florida.
He resigned from PLX's Board of Directors in 2007, and a 2010 U.S. Securities and Exchange Commission filing indicated that he donated around $8 million in Protalix shares to a charitable organization.
One thing that shorts like you don't take into account is that in the best case, you could never make more than a 80% profit, while been exposed all the time to a "margin call". On the other hand, people playing it from the "long side" could be able to make much more than 100% on their initial stake.
On PLX, for example, if you had sold it short at $45 and coveresd at $5 in 2007 (price adjusted for splits) you had made an 88.88% gain, (actually less than that, taking taking into account Regulation T).
But if you had bought it June 2009 and sold it in November 2009, you could have made more than a 1,800% gain on the LONG SIDE!!!
You could never have that kind of profit on the short side.
http://bit.ly/NsWfQ6;insttype=&fre...
Regarding OPKO and its OPK stock:
Yes, it is true that OPKO was initially focused on Ophthalmology, and the opthalmic instruments they bought from OTI are the best, according to several Ophthalmologists than I know that own more than one.
And it is also true that bevasiranib, was one of the top five most promising drugs entering Phase III clinical trials during the third quarter of 2007.
But like many other drugs, it was not able to meet its primary endpoint, and although preliminary data showed it had positive activity when used adjunctively with Gentech's Lucentis, OPKO decided to terminate its late-stage trial of Bevasiranib for the treatment of wet age-related macular degeneration in March 2009.
But that was also when Dr. P. Frost decided to enlarge OPKO's focus, and since then OPKO is no longer depending in one drug or one sector, since it is now a Health Care Company, with Pharmaceutical and Diagnostics Divisions, engaging in the discovery, development, and commercialization of novel and proprietary technologies primarily in the United States, Chile, and Mexico.
And from a "Technical" standpoint, in spite of this week's dip from the resistance at the $4.80 level, the stock remains on its longer term up-trend, which started in June 2009, when OPKO decided to enlarge its focus from just being "an Ophthalmology Company".
http://bit.ly/LqVimQ;insttype=&fre...
And my actual "average cost" on it is below $2, which still gives me a larger % gain than any that you could possibly obtain shorting this stock, or any other.
You say:
"Like Dr. Frost's predecessor company, Protalix, Opko's underlying products are worth far less than the current market capitalization, IN OUR OPINION."
I emphasize that last part, because i like to compare YOUR OPINION on shorting the stock, with Dr.Frost opinion, who has continued to buy OPKO's stock on a daily basis.
Comparing Protalix with OPKO is like comparing apples and oranges.
You said:
"We would not be the least bit surprised if Opko shareholders wake up one day and find that the share price has suddenly declined 50% or more."
And I think that I would not be surprised if OPK shares more than double in price, when some positive news comes out.
And there are quite a few possibilities for that in the near future.
Rolapitant is already on a PIII for nausea and vomiting in patients after anesthesia or receiving chemotherapy. The PIII shold not take long, it isn't costing OPKO any money, and GOOD RESULTS are very likely.
The PSA test in the CLAROS ANALYZER has already been approved in Europe, and OPKO has now licenced some biomarkers, which can significantly increase the reliability of that test, which could avoid 60% of biopsies now been performed on "false postive" results with the current PSA test. Be careful, because "News" on that could come out sooner than you think.
LabCorp is presently working on a Blood Test for AD, based on the biomarkers discovered by OPKO. That would be a commercially available test, something that was not possible with OPKO's low throughput microarray platform. It isn't costing OPKO any money, but you also better be ready when NEWS do come out.
There are also many other possible NEWS that could surprise you sooner than you apparently think, like results on a Blood Test for Neruromyelitis Optica; results on LCP6 on blood test for NSCLC; results from SR-3306 or other inhibitors of JNK on degenerative diseases,like Parkinson's,MS, ALS or AD.
Actually, I am as excited about OPKO's possible winning products, as I was back in 1967 when I bought Tool Research and Engeneering based on its "honeycomb" product for atenuation of the noise of the supersonic transport plane.
And TRE that year went from $3 to $90.
Try to accomplish that with your short selling. !!!
It also reminds me of Resorts International, which had evolved from Mary Carter Paints, (a more radical transformation than in OPKO's origins.)
The stock was down to $3 in the Summer of 1976 (it had been above $60 before the bear market in 1974)
But after the cassinos were approved in Atlantic City in November 1976, the stock which had been trading around $3 was up to $60 by June 1997 and then when its cassino opened it went to $200 in less than two days.
Can you possibly expect something like that happening using your "short technique"?
There is no question that OPKO is now one of the LARGEST SHORT TRAPS around.
And there could be a SHORT SQUEEZE or an STAMPEDE to COVER on any of the aforementioned "POSSIBLE NEWS"
@someconcerns..I understand..just don't invest on anything but your own DD and confidence that you have..that is all I do..I don't care what anyone says..I go with my gut and it has served me well...on SA always read the comments...here is another....
This is one of the most irrelevant and skewed articles I've ever read. Based on your previous work, as many have already mentioned, you are hardly the person who should be making comments on the future of OPKO Health.
I will give you this; you're pretty good at twisting facts and drawing illogical conclusions that perhaps your "followers" may believe. I have to hand it to you, you almost convinced me that Dr. Frost supports fraudulent Chinese companies; that is the way it sounded by the way you reported. The way you write, you'd think Dr. Frost is an investment God of some sort who has a horrible past of failing his "people." Dr. Frost is an individual, a very wealthy and successful one at that, who has made many extremely high-payout investments with his own money. He doesn't force anyone to follow his investments, unlike the way you make it sound in this article. However, he does maintain a large following because of his large portfolio of successful investments, evident in his astounding net worth, whether you like it or not.
I'm also wondering why you're even criticizing Dr. Frost in the first place. Why do you care where and how much he chooses to invest? You make it sound like a bad thing that Dr. Frost sticks with companies even when they aren't performing that well. Above anything else, it's a sign of loyalty as well as a strong stance of faith from the respected investor who will likely help the company he has a stake in to turn around. As noted by someone above, SafeStitch may have taken a turn for the worse, but since January it has been climbing back up; do you think it'd be continuing to climb if Dr. Frost ditched the company in a rough time? No. And all you can focus on is the companies failure to succeed.
It seems you really needed to do a lot of research to find poor investments he has made; Dr. Frost has made a lot more smarter decisions than failed investments. Regardless, the ones that have failed don't need to be criticized. Why does it matter if a risk, that was KNOWN to be a risk, ended up not working out? It's his money, and he chose to take that risk. You act like he is to blame for leading on investors who may be following his decisions.
You are a great writer when it comes to skewing facts and tricking the general public who don't have a basic knowledge of investing or Dr. Frost. Other than that, you're not much. As far as Protalix goes, Dr. Frost has actually made $70 million overall, but of course the only reference you could make was that he lost $300 million in a day. As for most other "losses," you seemed to only claim them in market valuation, failing to denote actual dollar loss, as mentioned above by gregsilver. As far as OPKO Health goes, you again only seem to notice the negatives. First of all, they are in a good position currently, and all you can talk about is the possibility of them failing. Sure, there's a possibility, but there's also a much better chance that they will succeed, especially with the help of Dr. Frost and his will to stick by them even when they're in the gutter. If he wanted to, Dr. Frost could buy back 2/3 of the float, or even the entire float of OPKO Health, which would most likely boost the stock to somewhere around $9.
Just for the sake of it, here's some more investments Dr. Frost has successfully made:
-Dreams
-ContinuedCare
-Whitman Education
-Key Pharmeceutical
-Ivax
-North American Vaccine
-Prolor
-ChromaDex
These probably don't count though, right?
I'd tell you to do your research next time you write an article, but it's clear that you have. Next time, though, spend more time researching both sides of the story instead of reporting a skewed article that does nothing but make you look like a bashful, immature, and uneducated writer.
someconcerns..it didn't offend me but like other people who take things with a grain of salt I take seeking alpha with an Advil..they give me a friggen headache with their crap...read this.. it is one of the comments directed towards this guy...and from me, notice how in his articles he refers to we this and we that but makes the mistake at the bottom disclosure of saying I AM SHORT instead of we are short....
Lets analyze some of your previous 'articles,' to see what your batting average is compared to that of Dr. Frost.
On May 22, 2012 you came out with an 'article' titled "Stem Cell Hype Has Yet To Breed Profits" bashing several stocks.
One of them was OSIR: "Things are no better at Osiris Therapeutics (OSIR), where the company's stem cell therapy, Prochymal, has now failed yet another trial. In its most recent test, Prochymal was unable to slow the progression of Type 1 diabetes. We can now include diabetes in the list of medical conditions which Prochymal has failed to successfully treat, which also includes graft-versus-host disease, Crohn's disease, heart attack, and knee cartilage repair. Osiris shares continue to fall, and reached a new all-time low late last year."
On that date, OSIR closed at 5.95 today is at 8.07. Anyone who would have shorted OSIR based on your article would be losing 35% in a little less than a month.
Regarding BTX "As we have explained in our previous articles, despite BioTime's (BTX) old Hextend business continuing its rapid descent into irrelevancy and seeing its two promoted replacement business models - a research grant collector and/or a "picks and shovels" play on the stem cell industry - fail, its stock continues to sport a $200 million market capitalization. This alone has been bizarre enough. But BioTime's lofty share price is even more strange when one considers that the rest of the stem cell industry has been in a brutal unrelenting decline while BioTime has risen out of the ashes."
BTX was 4.26 then is 4.33 now. No impact. You stated in your 'article' that you were short BTX, and a few days earlier had posted another two 'articles' bashing the company.
On March 13, 2012, you wrote an 'article' pumping VRX: "Valeant: Well Managed For A Promising Future" and you stated that you were long VRX.
On that date, VRX closed at 54.57, yesterday it closed at 45.65, a loss of 15.75% since then.
It seems to me that at this rate of 'success,' it would be better for you to short those stocks where you are bullish and go long on those where you are bearish.
Otherwise, Apshara may not be around much longer.
READ THE BOTTOM: Disclosure: I am short OPK. He has been on yahoo mb's and who knows how many others bashing opk BECAUSE HE IS SHORT...u don't even know who these guys are that write this crap...no background...look him up...seeking alpha puts out recruitment telling these people that they don't care what they write and it doesn't even have to be true..they don't check or verify anything so come write for us....they are just looking for any article...
he is putting out 3 articles he said on yahoo and this is the 2nd basher article...read the comments below all of them because they rebut everything this guy puts out....
just to let u know after someone on yahoo mb posted a file to fill out for the sec to report him for his untruths...he removed all of his postings....everyone on that mb gave him a hard time
This is their next product...Want to Boost Mitochondrial Function? Lose Weight? Got Nicotinamide Riboside?.....
Link:http://www.prohealth.com/library/showarticle.cfm?libid=17048
I own OPK and CDXC..Frost actually owns 19% of cdxc
from your mouth to our pockets...would be nice...
norkel...where are u getting your #'s lol
Headlines make people lose track of the real deal..don't forget about everything else they have going on...Blu is just the beginning...remember this....
http://investors.chromadex.com/phoenix.zhtml?c=212121&p=irol-newsArticle_pf&ID=1557940&highlight=
Rain..with respect I think you are wrong..why would they give away their marketing rights for Blu to someone else when that is exactly the direction that Frank Jaksch has been working so hard for..to take the company in that direction of putting out their own products on the shelf......ChromaDex is Frank Jaksch's company..has been and will continue to be...listen again to him and he flat out says this is the first of many products that they are going to bring to market which is a direct result of their ability to know before others what is being studied because of their database..the database is the foundation and the products will be major money for them..
on another note...IMHO I think they were let go..Jaksch didn't like the losses the co took the first Q on the coupon deal...
Teva Executive Key To Billionaire's Fortune Building
Frost is setting up for something big here..1st Himmel and now Levin..Link:http://seekingalpha.com/article/650021-teva-executive-key-to-billionaire-s-fortune-building?source=google_news
Rainmaker...I just bought into cdxc last couple days...started researching it because I own OPKO HEALTH...added to my position yesterday but hesitant today...went back again and studied volume but last couple days seem really low...especially today,only 6 trades...are we in a wait and see based solely on study results...would appreciate your opinion...TIA
They need to release the results, they have been finished for a long time and the last time they did a change was like april 12th or something and that was only verbage on a Dr.'s title.
On one of the Redchip videos on youtube when asked they said they were already setting up to move up, that is why last yr they voted on a reverse split so they would be ready.